The danger zone: Systematic review of the role of HMGB1 danger signalling in traumatic brain injury.
Taylor M Parker, Austin Huy Nguyen, Joshua R Rabang and 2 others
PMID 27819487WHAT IT FOUND
HMGB1 levels in blood and spinal fluid rise after brain injury and predict death or severe disability.
Animal studies show blocking HMGB1 reduces brain swelling and improves movement. These are biomarker and preclinical findings, not tested treatments for patients.
Key findings
01Higher HMGB1 levels in spinal fluid or plasma were independently associated with poor outcome or death after traumatic brain injury.
02In animal models, treatments that inhibited HMGB1 reduced brain swelling, protected the blood-brain barrier, and improved motor function.
03The review included only eight studies, comprising four human and six animal investigations, limiting the strength of evidence.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The review included only eight studies, a small number for a systematic review. Most therapeutic findings are from animal models, not human trials. HMGB1 levels were measured using ELISA or Western blot, which do not describe the protein's functional activity or distinguish its source (necrotic cells vs immune cells). The role of HMGB1 in inflammation may change over time, acting as pro-inflammatory early and potentially inactive or anti-inflammatory later. Patient heterogeneity (severity, type, location, age, sex) affects outcomes and was not fully controlled for in the included studies.
Declared interests
No conflicts of interest or funding sources are declared in the provided text.
The easy way to misread this
Do not interpret the animal studies showing reduced swelling and improved motor function as evidence that HMGB1-targeting treatments are available or effective for human patients. These are preclinical findings with no human therapeutic trials included in this review.